Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 9/20 | 0.76 |
| ▸ | GRIN3B | O60391 | 9/20 | 0.76 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.76 |
| ▸ | GRIN2A | Q12879 | 9/20 | 0.76 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.76 |
| ▸ | GRIN2C | Q14957 | 9/20 | 0.76 |
| ▸ | GRIN3A | Q8TCU5 | 9/20 | 0.76 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14326949 | 0.88 | GRIN2D (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1292034 | 0.87 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL121942 | 0.79 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5155436 | 0.78 | GRIN2D (0.73) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21676446 | 0.78 | GRIN2D (0.73) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1291817 | 0.78 | GRIN2D (0.73) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18308359 | 0.78 | GRIN2D (0.73) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22199001 | 0.77 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31475452 | 0.77 | GRIN2D (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7882415 | 0.75 | GRIN2D (0.62) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-02-06 | — | — | US | disclosed |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-02-06 | — | — | US | disclosed |
| EP-1397434-B1 | BASIC MONOAZO COMPOUNDS | CLARIANT FINANCE BVI LTD (VG) | 2012-12-26 | — | — | EP | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
| US-7183409-B2 | Basic mono- and bisazo compounds | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | BRD4, BET1, BRD3 | GRIN2D 4382/4885GRIN3B 3751/4885GRIN1 2316/4885 |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | BRD4, BET1, BRD3 | GRIN2D 4401/4885GRIN3B 3824/4885GRIN1 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.